Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Merck Issues Update On Next Steps For TREDAPTIVE - Quick Facts

Merck (MRK: Quote), known as MSD outside of the United States and Canada, said it is taking actions to suspend the availability of TREDAPTIVE tablets globally. TREDAPTIVE is not approved for use in the U.S. These steps are taken based on the current understanding of the preliminary data from the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events or HPS2-THRIVE study, and in consultation with regulatory authorities.

As reported earlier by the healthcare giant, HPS2-THRIVE failed to meet its primary endpoint of reduction of major vascular events, and there was a statistically significant increase in the incidence of some types of non-fatal serious adverse events in the group that received TREDAPTIVE compared with statin therapy. This suspension of availability of the medicine is aligned with the recommendation of the European Medicine Agency's Pharmacovigilance Risk Assessment Committee or PRAC, based on the study results.

In places where the medicine is currently available, Merck has started informing regulatory agencies of the company's decision. Merck is working with these agencies to develop communications for health care providers and to suspend the availability of TREDAPTIVE, with the timing to be based on individual country regulations and processes. Also, the healthcare giant is recommending that physicians stop prescribing TREDAPTIVE. Merck is also recommending that physicians review treatment plans for patients taking TREDAPTIVE in a timely manner to discontinue TREDAPTIVE and consider other changes in therapy to achieve their dyslipidemia management goals.

Register
To receive FREE breaking news email alerts for Merck & Co Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Specialty drugmaker Horizon Pharma plc (HZNP) on Friday managed to redomicile itself as an entity incorporated in Ireland following the completion of its $660 million acquisition of Vidara Therapeutics International plc. The deal will help it avoid paying the high rate of U.S. corporate taxes. The... Stocks showed a lack of direction over the course of the trading day on Friday after failing to sustain an initial upward move. Despite the choppy trading, the Dow once again managed to end the session at a new record closing high. The major averages turned in a mixed performance on the day. President Barack Obama delivered a statement Thursday evening thanking members of Congress for voting to approve legislation granting the U.S. military the authority to train and arm moderate Syrian rebels fighting against the terrorist group known as the Islamic State.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.